Evercore ISI downgraded Rocket Pharmaceuticals (RCKT) to In Line from Outperform with a price target of $5, down from $18, following this week’s “sad news” that a patient passed away in the company’s Danon disease trial. The analyst, who is also removing Rocket from the firm’s “SMID Core List,” thinks there are still “serious dilution concerns” and thinks the path to address this is to sell off the LVV platform. There is a lot of uncertainty around next steps, including timelines, and the firm doesn’t think “Danon alone is an attractive investment case from here, even if approvable,” the analyst added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Rocket Pharmaceuticals downgraded to In Line from Outperform at Evercore ISI
- Rocket Pharmaceuticals downgraded to Neutral from Overweight at JPMorgan
- Rocket Pharmaceuticals price target lowered to $19 from $51 at Scotiabank
- Broadcom, Arista Networks initiated: Wall Street’s top analyst calls
- Goldman downgrades Rocket to Sell on ‘surprising and concerning’ update
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue